Abstract Details

Title Validation of a Refined and Abbreviated Composite Autonomic Symptom Score

Topic Autonomic Disorders

Presentation(s) S37 - (-)

Poster/Presentation
Number 001

Background Standardized assessment of autonomic symptoms provides important information when evaluating autonomic failure in clinic and research. We previously described a comprehensive questionnaire, the autonomic symptom profile (ASP), and validated the use of a symptom score derived from this instrument, the composite autonomic symptom score (COMPASS). Recently, we developed a refined and much abbreviated score based on 31 key questions of the original ASP (COMPASS 31). We now sought to validate this new instrument by 1) assessing COMPASS 31 in subjects with different degrees of autonomic failure, 2) correlating COMPASS 31 with laboratory measures of autonomic function (CASS), and 3) assessing for agreement between COMPASS and COMPASS 31.

Objective

Design/Methods We recruited 33 patients with peripheral neuropathy (PN) and 39 patients with neurogenic autonomic failure (NAF) referred for evaluation to Mayo Clinic Rochester. 41 healthy controls were recruited from local communities. Subjects completed the ASP before undergoing standardized autonomic testing. COMPASS, COMPASS 31, and CASS scores were derived for all subjects. COMPASS 31 was assessed by comparing scores between groups, and by assessing associations with COMPASS and CASS.

Results COMPASS 31 and COMPASS were strongly associated across all groups (r=0.95, p<0.0001), and similarly within each patient group. A moderate association was seen between COMPASS 31 and CASS (Spearman's rho 0.66, p<0.0001), virtually identical to the association between COMPASS and CASS. Patients in the NAF group had significantly higher COMPASS 31 scores (39.2±17.6) than PN patients (20.9±13.0, p<0.0001) and controls (9.6±8.1, p<0.0001).

Conclusions These data establish the validity of COMPASS 31 as a concise instrument for the standardized assessment of autonomic symptoms. There is a very strong association with the original COMPASS, and - in spite of the markedly reduced number of questions - fully maintained separation of patient groups and association with CASS.

Authors/Disclosures
Wolfgang Singer, MD, FAAN (Mayo Clinic) PRESENTER	Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UniQure. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. The institution of Dr. Singer has received research support from NIH. The institution of Dr. Singer has received research support from FDA. The institution of Dr. Singer has received research support from Michael J. Fox Foundation. Dr. Singer has received intellectual property interests from a discovery or technology relating to health care.
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ)	Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has stock in NeuroRx.
	No disclosure on file
Jayawant N. Mandrekar, PhD	Dr. Mandrekar has nothing to disclose.
Phillip A. Low, MD, FAAN (Mayo Clinic)	Dr. Low has nothing to disclose.

��ɫ��

��ɫ��